Paula D Ryan, MD, PhD

Original Articles

1. Ryan PD, Hilf R. EGF receptors in R3230AC rat mammary carcinomas: characteristics and regulation in vitro and in vivo. Oncology Res 1992;4:181-92
2. Bastian LA, Lipkus IM, Juchibhatla MN, Weng H, Halabis S, Ryan PD, Skinner CS and Rimer BK. Women’s interest in taking chemoprevention for breast cancer. Arch Int Med 2001;161:1639-44
3. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friendlander RJ, Gargiulo J, Strenger R, Vogen CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman RG and Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95
4. Ma X-J, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG and Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16
5. Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;6(5):445
6. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come S, Schumert ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and Darbepoetin as Hematopoietic Support for Dose-Dense Every 2 Week Adjuvant Breast Cancer Chemotherapy. J Clin Oncol. 2005;20:23(33):8340-7
7. Shannon KM, Muzikansky A, Chan-Smutko G, Niendorf KB, Ryan PD. Uptake of BRCA1 rearrangement panel testing: In individuals previously tested for BRCA1/2 mutations. Genet Med. 2006;8(12):740-5
8. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. Clin Cancer Res. 2007 13:1198-1207
9. Lee J, Gazelle SG, Ryan PD, Halpern E, Weinstein M, McMahon P, Kopans DB. Effectiveness of MRI for Breast Cancer Screening in BRCA1 Gene Mutation Carriers: A Markov Monte Carlo Decision Analysis. Radiology.2008. 246(3):763-771
10. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of Rare Circulating Tumour Cells in Cancer Patients by Microchip Technology. Nature. 2007. 450(7173):1235- 1239
11. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber D, Van’t Veer LJ, Ramaswamy S. Analysis of the Mammarint Breast Cancer Assay in a Predonimantly Postmenopausal Cohort. Clin Cancer Res. 2008. 14:2988-2993
12. Chan-Smutko C, Patel D, Shannon KM, Ryan PD. Professional challenges in cancer genetic testing: Who is the patient? The Oncologist. 2008. 13:232-238
13. Burstein, HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SE, Shulman LN, Harris LN, Gelman R, Winer E. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 1; 14 (23): 7871-7
14. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010 Feb 11;12(1): R12
15. Lee JM, McMahon PM, Kong EY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS. Cost-effectiveness of breast MRI and film mammography for screening BRCA1 gene mutation carriers. Radiology. 2010 Mar;254(3):793-800
16. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J Clin Oncol. 2010 Mar 1;28(7):1145-53
17. Huntsman DG, Schrader K, Masciari S, Boyd N, Salamanca C, Senz J, Saunders D, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olufunmilayo OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Miron P, Confab K, Moore R, Southey M, Hopper J Garber JE. Germline mutations in CDH1 are infrequent in early-onset or familial lobular breast cancers. J Med
    Genet. 2010 Oct. 4 [Epub ahead of print]
18. Tung, N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szasz AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver D, Garber JE, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010 Nov 16;12 (6):R95.

Clinical Communications:

1. Ryan PD, Haber DA, Shannon KM, Smith BL, Fan MJ. Case Records of the Massachusetts General Hospital: A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. New England Journal of Medicine. 2003;349:1076-82
2. Ryan PD, Kopans DB, Sgroi DC. Case Records of the Massachusetts General Hospital: A 58-year- old woman with early-stage estrogen-receptor-positive breast cancer. New England Journal of Medicine. 2005;353(6):617-22
3. Ryan PD, Harisinghani M, Lerwill M, Kaufman D. Case Records of the Massachusetts General Hospital: Case 6-2006: A 71-year-old woman with urinary incontinence and a mass in the bladder. New England Journal of Medicine. 2006;354(8):850-6.

Reviews, Chapters, and Editorials:

1. Ryan PD, Chabner BA. On Receptor Inhibitors and Chemotherapy. Clin Cancer Res 2000;6:4607-09
2. Shannon KM, Niendorf KB, Ryan PD, Penson RT. Cancer Genetics. In: Facing Cancer. Eds. MA Sekeres and TA Stern 2004
3. Ryan PD, Goss PE. The Evolving Role of Aromatase Inhibitors in the Treatment of Early-Stage Breast Cancer. In: Natl Clin Pract Oncol. London, UK: Nature Publishing Group 2005;2(12):596-7
4. Ryan PD, Goss PE. Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer. The Oncologist. 2006;11(7):718-731
5. Cigler T, Ryan PD. Breast Oncology: Clinical Presentations and Genetics. In: Harrison’s Manual of Oncology. New York, New York: McGraw-Hill. 2007:511-520
6. Isakoff SJ, Ryan PD. Metastatic Breast Cancer. In: Harrison’s Manual of Oncology. New York, New York: McGraw-Hill. 2007:527-536
7. Ryan PD, Goss PE. Aromatase Inhibition In Breast Cancer: Update of Clinical Applications. In: Breast Cancer: Prognosis, Treatment, and Prevention (2nd Edition). New York, New York: Informa Healthcare. 2008: 169-180
8. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008 Jan; 13(1):16-24
9. Ryan PD, Shannon KM. Multidisciplinary Approach to the Prevention and Screening of Breast Cancer. Identification of High-Risk Patients. Breast Cancer: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. 2010 Chapter 2: 3-17

Thesis

Ryan, PD. Characterization and modulation of epidermal growth factor receptors in the R3230AC rat mammary adenocarcinoma [dissertation]. Rochester (NY): University of Rochester School of Medicine and Dentistry; 1990

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Ryan PD and Hilf R. Characterization and regulation of epidermal growth factors (egf) receptors in R3230AC rat mammary tumors. Proceedings of the American Association of Cancer Research 1988;247
2. Ryan PD and Hilf R. Effects of growth factors on R3230AC mammary tumors in vitro. Proceedings of the American Association of Cancer Research 1990;31:213
3. Burstein HJ, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Weissman CH, Sikov WM, Vogel Cl, Ryan PD, Ellis MJ, Harris LN, Bunnell CA, Campos SM, Hallor M and Winer EP. Multicenter Phase II Study of Trastuzumab (Herceptin; H) and Vinorelbine (Navelbine; N) as First- line Therapy for HER2 Overexpressing Metastatic Breast Cancer (HER2+MBC). Proceedings of the American Society of Clinical Oncology 2002; 114
4. Sgroi DC, Ma XJ, Ryan PD, Wang Z, Younger J, Isakoff S, Smith B, Brugge J, Baer TM, Erlander MG. Discovery of new gene expression predictors for adjuvant tamoxifen outcome for breast cancer patients. Proceedings of the American Society of Clinical Oncology 2004; 22 (14s):9503
5. Burstein HJ, Parker LM, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Bunnell CA, Come SE, Schumer ST, Haldoupis M, Gelman R, Winer EP. Use of the long-acting hematopoietic growth factors pegfilgrastim and darbepoetin alfa in support of dose-dense adjuvant chemotherapy. San Antonio Breast Cancer Symposium, 2004
6. Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnell CA, Partridge AH, Come SE, Ryan PD, Gelman R, Winer EP. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium. 2005
7. Harris L, Solomon N, Roberts L, Gioioso C, Abi Raad R, Borick H, Ngo T, Ryan PD, Kuter I, Gadd M, Smith B, Younger J, Friedman P, Taghian A. Detection and monitoring of circulating tumor cells (CTCs) by CK-19 mRNA in breast cancer patients treated with neoadjuvant chemotherapy: A marker of early recurrence. San Antonio Breast Cancer Symposium. 2005
8. Garber JE, Richardson A, Harris LN, Miron A, Silver D, Golshan M, Ryan PD, Ganesan S, Li X, Wang ZC, Clarke K, Tung NM, Iglehart JD, Winer EP. Neo-adjuvant cisplatin (CDDP) in “triple negative” breast cancer (BC). San Antonio Breast Cancer Symposium, 2006
9. Isakoff SJ, Leong CO, Vidnovic N, DeYoung MP, Goss PE, Ryan PD, Sgroi D, Ellisen L. p63/p73 Expression Mediates Cisplatin Sensitivity in a Subset of Triple-Negative Primary Breast Cancer: Implications for a New Clinical Trial. Oral Presentation, ASCO 2007 Annual Meeting, Chicago, IL
10. Shannon KM, Yamamoto K, Muzikansky A, Chan-Smutko G, Patel D, Ryan PD . BRCA1/2 Rearrangement Test (BART): Barriers to Utilization. Poster Presentation, National Society of Genetic Counselor 2008 Annual Educational Conference, Los Angeles, CA
11. Ryan PD, Neven P, Dirix LY, Barrios CH, Miller WH, Fenton D, Abraham MF, Paccagnella L, Gualberto A, Goss PE. Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer. Poster Presentation, San Antonio Breast Cancer Symposium. 2008
12. Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D’Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robspn M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. (#2108– Poster Presentation 12/12/08) Presented at the 31st Annual San Antonio Breast Cancer Symposium
13. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Proceedings of the American Society of Clinical Oncology 2009; 27(15s): 551
14. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. Proceedings of the American Society of Clinical Oncology 2009; 27(15s): 55S
15. Shannon KM, Chan-Smutko G, Patel D, Gabree MJ, Ryan PD. Phenotype of BRCA ½ Large Genomic Rearrangements. Current Oncology 2009 Oct. Volume 16(5) 106
16. Lee JM, Kalnins A, Pisano ED, Gatsonis C, McMahon PM, Kong CY, Kopans DB, Ryan PD, Halpern EF, Gazelle GS. Comparative effectiveness and cost-effectiveness of digital mammography and MRI for breast cancer screening BRCA1 gene mutation carriers. Oral presentation, 2009 Radiological Society of North America annual meeting, 12/1/09
17. Golshan M, Garber J, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan PD. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Abstract#43 Oral Presentation, San Antonio Breast Cancer Symposium, 12/12/2009